COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB PLUS BEVACIZUMAB AS FIRST-LINE THERAPY FOR ADVANCED EGFR MUTATION-POSITIVE NON-SQUAMOUS NONSMALL CELL LUNG CANCER IN JAPAN

被引：0
|
作者：
Yoshioka, S. [1 ]
Chen, W. [2 ]
Maeda, T. [2 ]
Morimoto, K. [2 ]
Moriwaki, K. [3 ]
Shimozuma, K. [2 ]
机构：
[1] Ritsumeikan Univ, Kusatsu, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kyoto 26, Japan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE380
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
    Zhou, J.
    Jiang, G.
    VALUE IN HEALTH, 2020, 23 : S54 - S54
  • [2] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Holleman, M. S.
    Al, M. J.
    Uyl-de Groot, C. A.
    VALUE IN HEALTH, 2018, 21 : S3 - S3
  • [3] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Kim, Yong-Jin
    Oremus, Mark
    Chen, Helen H.
    McFarlane, Thomas
    Fearon, Danielle
    Horton, Susan
    PHARMACOECONOMICS, 2021, 39 (05) : 537 - 548
  • [4] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
    Yong-Jin Kim
    Mark Oremus
    Helen H. Chen
    Thomas McFarlane
    Danielle Fearon
    Susan Horton
    PharmacoEconomics, 2021, 39 : 537 - 548
  • [5] Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
    Adderley, Helen
    Ackermann, Christoph Jakob
    Califano, Raffaele
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [6] Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
    Cai, Hongfu
    Zhang, Longfeng
    Li, Na
    Chen, Shen
    Zheng, Bin
    Yang, Jing
    Weng, Lizhu
    Liu, Mao-Bai
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 280 - 290
  • [7] First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis
    Zhang, Mengyao
    Sun, Lan
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [8] Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy
    Wu, Bin
    Gu, Xiaohua
    Zhang, Qiang
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 184 - 193
  • [9] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
    Yamamoto, N.
    Seto, T.
    Nishio, M.
    Goto, K.
    Okamoto, I
    Yamanaka, T.
    Tanaka, M.
    Takahashi, K.
    Fukuoka, M.
    LUNG CANCER, 2021, 151 : 20 - 24
  • [10] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
12345